HK1259440A1 - 包含btk抑制剂的配制品/组合物 - Google Patents
包含btk抑制剂的配制品/组合物 Download PDFInfo
- Publication number
- HK1259440A1 HK1259440A1 HK19101844.5A HK19101844A HK1259440A1 HK 1259440 A1 HK1259440 A1 HK 1259440A1 HK 19101844 A HK19101844 A HK 19101844A HK 1259440 A1 HK1259440 A1 HK 1259440A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- formulations
- compositions
- btk inhibitor
- ibrutinib
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621001986 | 2016-01-19 | ||
| IN201621001986 | 2016-01-19 | ||
| PCT/EP2017/050962 WO2017125423A1 (en) | 2016-01-19 | 2017-01-18 | Formulations/compositions comprising a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1259440A1 true HK1259440A1 (zh) | 2019-11-29 |
Family
ID=57851067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19101844.5A HK1259440A1 (zh) | 2016-01-19 | 2017-01-18 | 包含btk抑制剂的配制品/组合物 |
| HK19101838.3A HK1259434A1 (zh) | 2016-01-19 | 2017-01-18 | 包含btk抑制剂的配制品/组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK19101838.3A HK1259434A1 (zh) | 2016-01-19 | 2017-01-18 | 包含btk抑制剂的配制品/组合物 |
Country Status (23)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| DK3405178T3 (da) * | 2016-01-19 | 2025-09-22 | Janssen Pharmaceutica Nv | Formuleringer/sammensætninger, der omfatter en btk-inhibitor |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| CN109790121B (zh) | 2016-10-06 | 2024-01-05 | 詹森药业有限公司 | 用于制备btk抑制剂的方法和中间体 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN111278433A (zh) | 2017-09-26 | 2020-06-12 | 特沙诺有限公司 | 尼拉帕尼制剂 |
| US11576917B2 (en) | 2018-01-20 | 2023-02-14 | Natco Pharma Limited | Pharmaceutical compositions comprising Ibrutinib |
| KR102844084B1 (ko) | 2018-06-15 | 2025-08-07 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| US10688050B1 (en) * | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CN117064862B (zh) * | 2023-04-10 | 2025-12-19 | 山东新时代药业有限公司 | 一种伊布替尼肠溶片及其制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO1994008568A1 (fr) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Procede pour fabriquer des matrices de cire |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US20150152115A1 (en) * | 2007-12-27 | 2015-06-04 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| EP2902016A1 (en) * | 2014-01-30 | 2015-08-05 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Febuxostat tablet |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
-
2017
- 2017-01-18 FI FIEP17700820.8T patent/FI3405177T3/fi active
- 2017-01-18 JP JP2018537505A patent/JP7109365B2/ja active Active
- 2017-01-18 AU AU2017208472A patent/AU2017208472B2/en active Active
- 2017-01-18 BR BR112018014590-4A patent/BR112018014590A2/en not_active Application Discontinuation
- 2017-01-18 WO PCT/EP2017/050962 patent/WO2017125423A1/en not_active Ceased
- 2017-01-18 US US16/071,448 patent/US20190282577A1/en not_active Abandoned
- 2017-01-18 MX MX2018008771A patent/MX2018008771A/es unknown
- 2017-01-18 HK HK19101844.5A patent/HK1259440A1/zh unknown
- 2017-01-18 ES ES17700820T patent/ES3071000T3/es active Active
- 2017-01-18 HR HRP20260680TT patent/HRP20260680T1/hr unknown
- 2017-01-18 LT LTEPPCT/EP2017/050962T patent/LT3405177T/lt unknown
- 2017-01-18 EA EA201891440A patent/EA201891440A1/ru unknown
- 2017-01-18 EP EP17700820.8A patent/EP3405177B1/en active Active
- 2017-01-18 PL PL17700820.8T patent/PL3405177T3/pl unknown
- 2017-01-18 SM SM20260226T patent/SMT202600226T1/it unknown
- 2017-01-18 CN CN201780006752.0A patent/CN108472259A/zh active Pending
- 2017-01-18 PT PT177008208T patent/PT3405177T/pt unknown
- 2017-01-18 DK DK17700820.8T patent/DK3405177T3/da active
- 2017-01-18 KR KR1020187023222A patent/KR102974264B1/ko active Active
- 2017-01-18 HK HK19101838.3A patent/HK1259434A1/zh unknown
- 2017-01-18 RS RS20260662A patent/RS68165B1/sr unknown
- 2017-01-18 MA MA43649A patent/MA43649B1/fr unknown
- 2017-01-18 KR KR1020267017580A patent/KR20260093426A/ko active Pending
- 2017-01-18 CN CN202610206777.6A patent/CN122097373A/zh active Pending
- 2017-01-19 TW TW106101783A patent/TWI803454B/zh not_active IP Right Cessation
- 2017-01-19 AR ARP170100141A patent/AR107391A1/es unknown
-
2018
- 2018-07-17 MX MX2024009894A patent/MX2024009894A/es unknown
- 2018-07-17 MX MX2022006768A patent/MX2022006768A/es unknown
-
2022
- 2022-04-07 JP JP2022063871A patent/JP2022105009A/ja not_active Withdrawn
- 2022-05-04 US US17/736,305 patent/US20220339157A1/en active Pending
- 2022-11-25 AU AU2022275514A patent/AU2022275514A1/en not_active Abandoned
-
2023
- 2023-10-25 JP JP2023183050A patent/JP7887878B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006768A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| HK1259441A1 (zh) | 包含btk抑制剂的制剂/组合物 | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| EP3484504A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE | |
| WO2017136450A3 (en) | Compounds and methods of treating rna-mediated diseases | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| WO2015148863A3 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| HK1246286A1 (zh) | Lrrk2抑制剂及其制备和使用方法 | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| WO2016004807A3 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta | |
| HK1248069A1 (zh) | 去乙酰氧基微管溶素h及其类似物 | |
| WO2015123449A3 (en) | Compositions and methods of using microrna inhibitors | |
| WO2015179823A3 (en) | Lung localized inhibitors of alpha(v)beta 6 | |
| WO2015120372A3 (en) | Compositions and methods to inhibit ezh2 for the treatment of cardiovascular diseases | |
| PH12017501130A1 (en) | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| MX382092B (es) | Compuestos heterocíclicos para el tratamiento de enfermedades. | |
| WO2017214423A3 (en) | Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof | |
| MX2025015454A (es) | Formulaciones/composiciones que comprenden ibrutinib | |
| WO2015130547A8 (en) | Bis-cyclic guanidine compound compositions, methods of use and treatment thereof | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease |